Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: A multicenter study

International Journal of Hematology

Volumn 74, Issue 2, 2001, Pages 144-146

  Chuncharunee, Suporn ^a   Intragumtornchai, Tanin ^b   Chaimongkol, Boonsom ^c   Prayoonwiwat, Wichai ^d   Leelasiri, Apichai ^d   Lekhakula, Arnuparp ^e   Chansung, Kanjana ^f   Yoshida, Yataro ^g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^d PRAMONGKUTKLAO HOSPITAL   (Thailand)

^e PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^f Department of Psychiatry   (Thailand)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

Low dose G CSF; MDS; Neutropenia; Thai multicenter study

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOPOIESIS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 0035430466     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02981996     Document Type: Article

References (14)

1. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
2. Greenberg PL, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
3. Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. 1989;110:976-982.
4. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76: 36-43.
5. Yoshida Y, Hirashima K, Asano S, Takaku F. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol. 1991;78:378-384.
6. Estey EH, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol. 1991;77:291-295.
7. Greenberg PL. Treatment of myelodysplastic syndromes with haemopoietic growth factors. Semin Oncol. 1992;19:106-114.
8. Greenberg PL, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS) [abstract]. Blood. 1993;82(suppl 1):196a.
9. Yoshida Y, Uchino H, Maekawa T, et al. Long-term administration of G-CSF in the myelodysplastic syndromes (MDS) [abstract]. Exp Hematol. 1995;22:920a.
10. Geissler RG, Schulte P, Ganser A. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes, Int J Hematol. 1997;65:339-354.
11. Hansen PB, Penkowa M, Jonsen HE. Hematopoietic growth factors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 1998;28:491-500.
12. Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes, Int J Hematol. 1999;70:141-154.
13. Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. Int J Hematol. 2000;72: 134-138.
14. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res. 1998;22:453-460.